6
Registered trials
3
Recruiting
5
Unique sponsors
6
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
3
N
Neurology/Psychiatry (ATC N)
1
A
Gastroenterology (ATC A)
1
B
Haematology (ATC B)
1
C
Cardiology (ATC C)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
5 substances
SGLT2 inhibitor
1 substance
Phase III:
3
Phase II:
1
Phase I/II:
1
Phase IV:
1
Phase III
3 trials-
RecruitingAssistance Publique Hopitaux De Paris AcademicISOFLURANE
-
RecruitingCHRU De Nancy AcademicEMPAGLIFLOZIN
-
RecruitingCHRU De Nancy AcademicLEVOSIMENDAN; PANTOTHENATE SODIUM, RIBOFLAVIN SODIUM PHOSPHATE, BIOTIN, CYANOCOBALAMIN, FOLIC ACID, NICOTINAMIDE, SODIUM ASCORBATE, THIAMINE NITRATE, PYRIDOXINE HYDROCHLORIDE; RETINOL PALMITATE, ASCORBIC ACID, BIOTIN, COLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NICOTINAMIDE, PYRIDOXINE HYDROCHLORIDE, DL-ALPHA-TOCOPHEROL, COCARBOXYLASE TETRAHYDRATE
Phase II
1 trial-
EndedWindtree Therapeutics Inc. CommercialISTAROXIME
Phase I/II
1 trial-
Halted4TEEN4 Pharmaceuticals GmbH CommercialIMP not specified
Phase IV
1 trial-
EndedAzienda Unita' Sanitaria Locale Toscana Sud Est AcademicIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| CHRU De Nancy | Academic | 2 | Phase III | 2 |
| Windtree Therapeutics Inc. | Commercial | 1 | Phase II | 0 |
| 4TEEN4 Pharmaceuticals GmbH | Commercial | 1 | Phase I/II | 0 |
| Assistance Publique Hopitaux De Paris | Academic | 1 | Phase III | 1 |
| Azienda Unita' Sanitaria Locale Toscana Sud Est | Academic | 1 | Phase IV | 0 |
New trials by year
2023
1
2024
1
2025
3
2026
1